2022
Illness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.Peer-Reviewed Original ResearchIllness phasePotential critical windowsPhase-specific biomarkersDopaminergic abnormalitiesFunctional outcomeSpecialty careSymptom assessmentIllness stageChronic illnessClinical assessmentIllness trajectoryNeurophysiological biomarkersFunctional abnormalitiesClinical careEarly psychosisMemory dysfunctionPsychotic disordersTreatment targetsAllostatic adaptationIntervention windowClinical programsBrain developmentCritical windowDysfunctionIllness
2021
Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom
Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim HC, Paulus MP, Krystal JH, Jeste DV. Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2021, 6: 856-864. PMID: 33571718, PMCID: PMC8349367, DOI: 10.1016/j.bpsc.2021.02.001.Peer-Reviewed Original ResearchConceptsMental health careMental illnessHealth careMental health care providersHigh-risk individualsHealth care providersElectronic health recordsHigh morbiditySound careStudy groupAmerican CollegeCare providersPsychiatric disordersOwn careProdromal stageClinical diagnosisBrain imagingHealth recordsIllnessCareClinical applicationHealth care fieldIllustrative publicationsTreatmentNeurobiological research
2020
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Abdallah CG, Krystal JH. Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression? Behavioural Brain Research 2020, 390: 112628. PMID: 32407817, PMCID: PMC7316409, DOI: 10.1016/j.bbr.2020.112628.Peer-Reviewed Original ResearchConceptsChronic stress pathologyRapid acting antidepressantsHigh treatment resistanceActing antidepressantsChronic courseClinical evidenceLeading causeTreatment resistancePsychiatric disordersStress pathologyDepressionLarge proportionAntidepressantsPatientsReviewKetamineIllnessPathologyComprehensive review
2019
Altered functional connectivity and low-frequency signal fluctuations in early psychosis and genetic high risk
Tang Y, Zhou Q, Chang M, Chekroud A, Gueorguieva R, Jiang X, Zhou Y, He G, Rowland M, Wang D, Fu S, Yin Z, Leng H, Wei S, Xu K, Wang F, Krystal JH, Driesen NR. Altered functional connectivity and low-frequency signal fluctuations in early psychosis and genetic high risk. Schizophrenia Research 2019, 210: 172-179. PMID: 30685394, DOI: 10.1016/j.schres.2018.12.041.Peer-Reviewed Original ResearchConceptsFunctional connectivityHigh-risk individualsAltered functional connectivityHealthy comparison subjectsGenetic high riskGenetic high-risk individualsLow-frequency signal fluctuationsFunctional magnetic resonanceALFF abnormalitiesALFF measuresFunctional connectivity measuresBasal gangliaFirst episodeHigh riskEarly psychosisComparison subjectsSchizophrenia diathesisSchizophrenia vulnerabilityFESzGenetic riskLow-frequency fluctuationsIllnessSchizophreniaVoxel connectivityGHR
2016
The Connecticut Mental Health Center: Celebrating 50 Years of a Successful Partnership Between the State and Yale University
Steiner JL, Anez-Nava L, Baranoski M, Cole R, Davidson L, Delphin-Rittmon M, Dike C, DiLeo PJ, Duman RS, Kirk T, Krystal J, Malison RT, Rohrbaugh RM, Sernyak MJ, Srihari V, Styron T, Tebes JK, Woods S, Zonana H, Jacobs SC. The Connecticut Mental Health Center: Celebrating 50 Years of a Successful Partnership Between the State and Yale University. Psychiatric Services 2016, 67: 1286-1289. PMID: 27691379, DOI: 10.1176/appi.ps.201600373.Peer-Reviewed Original Research
2013
Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness
Anticevic A, Cole MW, Repovs G, Murray JD, Brumbaugh MS, Winkler AM, Savic A, Krystal JH, Pearlson GD, Glahn DC. Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness. Cerebral Cortex 2013, 24: 3116-3130. PMID: 23825317, PMCID: PMC4224238, DOI: 10.1093/cercor/bht165.Peer-Reviewed Original ResearchConceptsThalamo-cortical systemThalamic connectivityBipolar illnessResting-state functional magnetic resonance imagingSensory-motor cortexSevere mental illnessFunctional magnetic resonance imagingMagnetic resonance imagingThalamic dysconnectivityThalamic seedsClinical presentationNeuropsychiatric syndromeBrain dysconnectivityThalamic nucleiBipolar patientsSchizophrenia patientsSensory gatingMental illnessResonance imagingDysconnectivityCerebellar regionsDiagnostic membershipPrefrontal cortexSchizophreniaIllnessTranslational cognitive neuroscience of schizophrenia: bridging neurocognitive and computational approaches toward understanding cognitive deficits
Anticevic A, Krystal J, Barch D. Translational cognitive neuroscience of schizophrenia: bridging neurocognitive and computational approaches toward understanding cognitive deficits. 2013, 193-230. DOI: 10.1017/cbo9781139003872.013.Peer-Reviewed Original ResearchCognitive deficitsCognitive neuroscienceCourse of impairmentSevere mental illnessDeficitsSchizophreniaMental illnessPharmacological techniquesBiological contributionPrecise mechanismNeuroscienceIllnessLittle disputeRelated featuresStyleFunctional implicationsImpairmentManagement optionsImplicationsDisabilityPatientsSymptomsCliniciansDisease
2011
New Frontiers in Animal Research of Psychiatric Illness
Kaffman A, Krystal J. New Frontiers in Animal Research of Psychiatric Illness. Methods In Molecular Biology 2011, 829: 3-30. PMID: 22231804, PMCID: PMC3337084, DOI: 10.1007/978-1-61779-458-2_1.Peer-Reviewed Original ResearchConceptsPsychiatric illnessAnimal modelsMental illnessHuman psychopathologyValid animal modelCurrent animal modelsNumerous psychiatric disordersMore effective interventionsResearch Domain Criteria projectInternational ClassificationPsychiatric disordersMeasurable endophenotypesIllnessNeurodevelopmental changesSubstance abuseEffective interventionsAnxiety disordersStatistical ManualMolecular changesDevelopmental originsMental disorders diagnostic systemsCircuit developmentTranslational workAnimal researchBehavioral outcomes
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1998
Complications of alcohol withdrawal: pathophysiological insights.
Trevisan LA, Boutros N, Petrakis IL, Krystal JH. Complications of alcohol withdrawal: pathophysiological insights. Alcohol Research 1998, 22: 61-6. PMID: 15706735, PMCID: PMC6761825.Peer-Reviewed Original ResearchConceptsAcute alcohol withdrawalAlcohol withdrawalLong-term sobrietyDelirium tremensAcute withdrawalMental confusionSignificant illnessPathophysiological insightsDisease processPsychiatric problemsCognitive impairmentComplicationsHeavy drinkingMemory disordersWithdrawalDeliriumMedicationsRelapseTremensPatientsSeizuresIllnessImpairmentSeverityHallucinations
1997
The role of serotonin in the pathophysiology and treatment of schizophrenia
Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal Of Neuropsychiatry 1997, 9: 1-17. PMID: 9017523, DOI: 10.1176/jnp.9.1.1.Peer-Reviewed Original ResearchConceptsRole of serotoninBeneficial effectsSubcortical dopamine activityCerebrospinal fluid studiesCortex of patientsTreatment of schizophreniaBrain tissue analysisSerotonergic hypofunctionDopaminergic antagonistsPharmacological challengeDopamine activityNegative symptomsFluid studiesSchizophreniaPathophysiologySerotoninIllnessTissue analysisTreatmentMore researchAntagonismCompelling evidenceHypofunctionPatientsAntagonist
1986
Assessment of alexithymia in posttraumatic stress disorder and somatic illness: introduction of a reliable measure.
Krystal JH, Giller EL, Cicchetti DV. Assessment of alexithymia in posttraumatic stress disorder and somatic illness: introduction of a reliable measure. Psychosomatic Medicine 1986, 48: 84-94. PMID: 3945719, DOI: 10.1097/00006842-198601000-00007.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderBeth Israel Psychosomatic QuestionnaireSomatic illnessStress disorderOutpatient treatmentAffective patientsAffective disordersPsychiatric inpatientsPatientsSchalling-Sifneos ScaleComparison groupAssessment of alexithymiaMedical servicesInterrater reliabilityPsychosomatic researchVietnam veteransDisordersSimilar degreeInpatientsGreater degreePsychosomatic QuestionnaireIllnessMMPI subscalesSomatic groupsReliable measure